<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917640</url>
  </required_header>
  <id_info>
    <org_study_id>APBI Registry</org_study_id>
    <nct_id>NCT04917640</nct_id>
  </id_info>
  <brief_title>Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT)</brief_title>
  <official_title>Accelerated Partial Breast Irradiation (PBI) With Stereotactic Body Radiation Therapy (SBRT) or Intensity Modulated Radiation Therapy (IMRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenesisCare USA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenesisCare USA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a registry study that will be used to evaluate external beam radiation therapy&#xD;
      methods for the accelerated treatment of breast cancer. Patients are being asked to take part&#xD;
      in this registry because they have breast cancer and desire treatment with accelerated&#xD;
      partial breast irradiation to be delivered by external beam methods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    A revised study has been listed here for us.&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment and toxicity-related adverse events as assessed by CTCAE v4.0&quot;.</measure>
    <time_frame>Through study completion, an average of 12 months</time_frame>
    <description>Toxicity will be assessed using the CTCAEv4.0 and recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ipsilateral breast recurrence</measure>
    <time_frame>Through study completion, an average of 12 months</time_frame>
    <description>Number of participants with pathologically confirmed ipsilateral breast recurrence.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <description>Patients treated with Stereotactic Body Radiation Therapy (SBRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT</arm_group_label>
    <description>Patients treated with Intensity Modulated Radiation Therapy (IMRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Either SBRT or IMRT radiation therapy</description>
    <arm_group_label>IMRT</arm_group_label>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with greater than or equal to 50 years old and who have been diagnosed with Low to&#xD;
        intermediate DCIS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than or equal to 50 years old Low to intermediate DCIS Tumor size &lt; or = to&#xD;
             2cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BRCA positive Lobular histology Angiolymphatic invasion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women 50 years old or older who have been diagnosed with low to intermediate DCIS</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sharon Salenius, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GenesisCare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GenesisCare USA</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

